Clinical trial
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive…
NCT00485563 · Endocyte, Industry · Terminated
Key facts
| NCT number | NCT00485563 |
|---|---|
| Title | A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma |
| Official title | A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma |
| Lead sponsor | Endocyte, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Biological, Drug |
| Interventions | EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC), Interleukin-2, Interferon-alpha |
| Enrollment | 12 |
| Start date | Jun 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Jun 13, 2007 |
| Last update posted | Mar 8, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: